For the subset of these diseases in which eosinophilia is seen, our data suggest that targeting eosinophils could have therapeutic efficacy while avoiding potential toxicities such as impaired host defenses to infections that could occur following global inhibition of the IL-23/IL-17 axis [46]. Here, IL17A is linked to Increased total eosinophil count.